Senolytic Drug Combo Slows ALS Progression in Mouse Model
Cellular senescence emerges early in ALS pathology, and clearing senescent cells with dasatinib and quercetin improves motor function in mice.
Summary
Amyotrophic lateral sclerosis (ALS) is a fatal motor neuron disease closely tied to aging. Researchers at the University of Missouri found that hallmarks of cellular senescence — the same aging mechanism targeted by longevity researchers — appear early in the motor cortex and spinal cord of ALS mice before significant neurological decline. When these mice were treated with dasatinib and quercetin, a popular senolytic drug combination already being studied in aging contexts, they showed measurable improvements in motor behavior, neuromuscular function, and brain excitability, along with reduced axonal damage markers in the blood. Microglia, the brain's immune cells, appeared to be a key mediator of these benefits. The findings position cellular senescence as a targetable, early driver of ALS — and suggest that senolytics already in human trials for aging conditions could be repositioned for neurodegenerative disease.
Detailed Summary
ALS is a rapidly progressive and fatal neurodegenerative disease that destroys the motor neurons controlling voluntary movement. While aging is the single strongest risk factor for ALS, the specific aging mechanisms driving disease onset and progression have remained poorly defined — limiting the development of effective therapies.
Researchers used TDP-43(Q331K) transgenic mice, a well-established ALS model, to investigate whether cellular senescence — the irreversible cell-cycle arrest and inflammatory state that is a hallmark of aging — contributes to early ALS pathology. Molecular markers of senescence were systematically mapped in the motor cortex and spinal cord across disease stages, and their timing relative to functional decline was characterized.
The study found that senescence markers appeared in the motor cortex and spinal cord concurrent with the earliest measurable declines in neural and neuromuscular function — establishing senescence as an early, not merely incidental, feature of ALS pathology. Longitudinal treatment with dasatinib and quercetin (D&Q), a senolytic combination already being tested in human aging trials, produced significant benefits: improved motor behavior, enhanced motor cortex excitability, preserved layer V neuron counts, and reduced plasma neurofilament light chain — a validated blood biomarker of axonal damage. Cortical microglia showed reduced TDP-43 burden and senescence markers, implicating neuroinflammation as a key pathway through which senolytics exert their benefit.
For the longevity and brain health communities, these findings carry direct relevance. The dasatinib-and-quercetin combination is already one of the most studied senolytic protocols in human aging research. Demonstrating efficacy in an ALS model strengthens the case that senescence is a shared mechanism across multiple neurodegenerative conditions, not a disease-specific phenomenon.
Caveats include the preclinical, mouse-model nature of the work, and the summary here is based on the published abstract only, pending full-text review. Translation to human ALS will require clinical trials.
Key Findings
- Cellular senescence markers appear early in ALS mouse motor cortex and spinal cord, coinciding with first functional declines.
- Dasatinib and quercetin treatment improved motor behavior and neuromuscular function in TDP-43(Q331K) ALS mice.
- Plasma neurofilament light chain — a blood biomarker of axonal damage — was reduced by senolytic treatment.
- Motor cortex excitability and layer V neuron counts were preserved in D&Q-treated mice.
- Cortical microglia with reduced TDP-43 burden are implicated as a key mediator of senolytic benefit.
Methodology
The study used TDP-43(Q331K) transgenic mice, a validated genetic ALS model, and assessed molecular senescence markers longitudinally in the motor cortex and spinal cord. Senolytic treatment with dasatinib and quercetin was administered longitudinally, with outcomes including behavioral motor testing, electrophysiological measures of motor cortex excitability, neuron counts, and plasma neurofilament light chain levels. Microglial senescence and TDP-43 burden were evaluated at the cellular level.
Study Limitations
This study is preclinical and conducted entirely in transgenic mice; findings may not directly translate to human ALS. The TDP-43(Q331K) mutation represents one genetic subtype of ALS, and results may not generalize to sporadic cases, which constitute the majority of patients. This summary is based on the abstract only, as the full text was not available for review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: